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Background Patients with chronic inﬂammatory rheumatisms
(CIR) have a greater risk of cardiovascular events, infections, lung
diseases and osteoporosis. European League against Rheumatisms
(EULAR) recommends annual evaluation of the cardiovascular
risks.
Methods A program of comorbidity screening was set up in a
daily clinic of our Rheumatology department and includes:
– rheumatism evaluation;
– cardiovascular evaluation; clinical examination, blood tests,
modiﬁed systematic coronary risk evaluation (mSCORE) calcula-
tion, vessel ultrasound and echocardiography;
– lung evaluation; self-questionnaires and spirometry;
– osteoporosis; bone mineral density and FRAX calculation;
– check-up of vaccinal status and the recommended neoplasic
screenings.
Results Ninety-two patients already beneﬁted from this system-
atic screening with 83% (n = 76) of rheumatoid arthritis, 11%
(n = 10) of spondyloarthritis, 3% (n = 2) of psoriatic arthritis and 4%
(n = 4) of other diseases. The mean rheumatism duration was
14  9 years, the mean age was 59  11 years and 64% were women.
Hypertension was diagnosed in 8.7% (n = 8) of the patients;
dyslipidemia in 9.8% (n = 9); diabetes in 6.5% (n = 6) of the patients.
The echocardiography showed signiﬁcant abnormalities (valvular and
hypokinesia) in 9% (n = 8) of the patients, a signiﬁcant supra-aortic
vessel stenosis was found in 4.5% (n = 4) of the population and an
abdominal aortic aneuvrysmwas diagnosed in 5.7% (n = 5). Among 92
patients, 18.4% (n = 14) were estimated at high risk of lethal
cardiovascular event with a mSCORE  5 and 27.5% (n = 25) patients
were sent to a cardiologist to pursue further cardiovascular investiga-
tions. Among these, 8 had a myocardial scintigraphy and all were
normal. Moreover, 32.6% (n = 30) of the patientswere estimated at risk
of chronic obstructive pulmonarydisease or sleep apnea syndromeand
were recommended to consult pneumologist. An anti-osteoporosis
drug was introduced in 12% (n = 11) of the patients. The update of the
vaccinations and the neoplasic screenings were prescribed for
respectively 52.7% (n = 48) and 35.2% (n = 32) of the patients.
Discussion A daily hospitalization for comorbidity screening
seems worthy with signiﬁcant abnormalities discovered in 36.2%
of the patients. Further investigations were recommended in 50%
of the patients. Patient’ satisfaction and the effective impact of the
proposed or prescribed measures are under evaluation.
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Importance Physical therapy could be of interest to reduce
disability of systemic sclerosis (SSc) patients.
Objective To develop a physical therapy program for SSc and
compare its efﬁcacy with that of usual care.
Design 12-month, parallel-group randomized controlled trial
involving a modiﬁed Zelen design conducted between September
2005 and October 2011. Randomization was computer-generated
with allocation concealment by fax to a central coordinating ofﬁce.
Investigators were not blinded, but participants in the control
group were blinded to study hypothesis.
Setting Four tertiary-care hospitals.
Participants Patients were enrolled if they had a SSc diagnosis, a
disability rating  0.5 on the Health Assessment Questionnaire
Disability Index (HAQ-DI) or complaints of decreased mouth
opening or limited range of motion of at least one joint.
Interventions The experimental intervention was a 1-month
personalized supervised physical therapy program provided by
speciﬁcally trained care providers followed by home sessions. The
comparator was usual care.
Main outcomes and measures The primary outcome was the
HAQ-DI score at 12 months.
Results In the intention-to-treat analysis, as compared with the
usual care group (n = 108), patients in the physical therapy group
(n = 110) showed reduced disability at 1 month (HAQ-DI between-
group difference (0.14; 95% conﬁdence interval [CI] –0.24 to –0.03;
P = 0.01), at 6 months the HAQDI scores between-group difference
was –0.12; 95% CI, –0.23 to 0.01; P = 0.054. There was no
statistically signiﬁcant difference at 12 months (between-group
difference at 12 months, –0.01; 95% CI –0.15 to 0.13; P = 0.86).
There was a statistically signiﬁcant difference for hand mobility
and function, and pain, at 1 month but no difference at 12 months.
Microstomiawas lower in the physical therapy group at 1, 6 and 12
months (between-group difference at 12months, 1.62; 95% CI 0.32
to 2.93; P = 0.01). No differences in adverse effects were observed
between the two treatment groups.
Conclusions and relevance A 1-month personalized supervised
physical therapy program followed by home exercise sessions had
short-term beneﬁts for patients with SSc but did not reduce
disability at 12 months. The program had long-term beneﬁts for
microstomia.
Trial registration clinicaltrials.gov identiﬁer NCT00318188.
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Rheumatoid arthritis (RA) and Spondyloarthritis (SpA) control and
outcome have greatly improved with the efﬁcacy of biologic
disease-modifying anti-rheumatic drugs (bDMARDs) combined
with early effective management and treatment targeting remis-
sion or low disease activity. In addition, remission has now been
showed to be an achieving objective in the daily management
of patients with inﬂammatory arthritis. Overall, comparative
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analyses showed only minor differences with respect to efﬁcacy
and safety among the licenced bDMARDs. In RA (but not in SpA),
the optimum regimen is achieved by combination of any bDMARD
with synthetic DMARD such as methotrexate. Importantly,
increasing evidence supports an inﬂuence of bDMARDs on
prolonged survival of patients with RA, which is likely linked to
a reduction of cardiovascular risk factors. A careful selection of
eligible patients, a pretherapeutic screening, a tight control of
disease activity and therapeutic response and a strictmonitoring of
possible adverse events are keys points to improve the beneﬁt/risk
ratio of these major therapeutic innovations.
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